Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) - study protocol for a randomized controlled trial

Vladimir J Lozanovski, Philipp Houben, Ulf Hinz, Thilo Hackert, Ingrid Herr*† and Peter Schemmer*†

Abstract

Background: Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies with marked resistance to chemo- and radiotherapy. PDA-cancer stem cells (CSCs) are not targeted by current therapies and may be a reason for poor prognosis. Studies indicate that diets rich in cabbage, broccoli, and cauliflower offer cancer preventative and therapeutic benefits. Recent experimental studies have confirmed these findings and demonstrated that isothiocyanate, sulforaphane, and the polyphenol, quercetin, effectively reduced tumor growth and enhanced the sensitivity of the cancer cells to current chemotherapeutics. The aim of the present study is to test the feasibility of a randomized controlled trial on the application of freeze-dried broccoli sprouts in patients with advanced PDA.

Methods and study design: The study is designed as a prospective randomized, double-blinded pilot trial with a treatment and a placebo-controlled arm in a single center setting. A total number of forty patients (18 years or older) in two parallel groups with advanced, surgically non-resectable PDA under palliative chemotherapy are planned for recruitment. Patients in the treatment group will receive fifteen capsules of the study substance per day (90 mg of active sulforaphane) during the chemotherapy treatment course. Patients in the placebo group will receive the same capsule size and portion distribution with inactive substances (mainly methylcellulose). The follow-up duration is one year. Feasibility of the study substance, adverse effects, and patient compliance, as well as levels of serum tumor markers (CEA, CA 19-9), quality of life, and patient overall survival rates will be assessed at defined points of time.

Discussion: The POUDER trial is expected to transfer promising experimental and epidemiological data into a clinical pilot study to assess the effectiveness of broccoli sprout extracts in the treatment of advanced PDA. The study objectives will provide data on the clinical feasibility and acceptability of a supportive treatment option accompanying palliative chemotherapy. Based on these results, future clinical studies to create further evidence in this field are possible.

Trial registration: The POUDER trial has been registered at ClinicalTrials.gov with an ID NCT01879878 and WHO with an ID U1111-1144-2013 on June 13th 2013.

Keywords: Pancreatic adenocarcinoma, broccoli sprouts, sulforaphane, palliative chemotherapy, cancer stem cells

Background

Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cause of cancer-related deaths worldwide. It is one of the most aggressive and lethal malignancies, with a 5-year survival rate of 6% in Europe and the United States, and a median survival time of 4 to 6 months [1-3].

With an incidence proportionally correlated to age [1], the numbers of estimated new cases and PDA-related deaths for 2013 in the United States alone are 45,220 and 38,460, respectively [4]. Despite standardization and advances in surgical and systemic treatment options, curative surgical intervention is possible in only 20% of the patients [5], due to the cancer’s initial asymptomatic course. Most patients present with an advanced stage of disease and can therefore only be treated in a palliative intention, which explains the nearly similar rates of
incidence and mortality [1,6]. PDA-specific molecular aberrations, intense desmoplastic stroma reaction, and hypoxia are some of the factors that presumably cause the poor outcome [7].

Recent research data strongly suggest that cancer is a stem cell disease [8,9]. The small subpopulation of cancer stem cells (CSCs) within the tumor mass is thought to survive during conventional cytotoxic therapy due to its defense and survival mechanisms [10]. CSCs are believed to be capable of self-renewal and differentiation, thereby generating a heterogeneous cell population of the original tumor [8,11,12]. In addition, it has been proposed that CSCs mediate uncontrollable growth, therapy resistance, cell invasion, and metastasis [13]. Markers for CSCs have been identified in various tumor entities, including PDA, and selected marker-positive cell fractions are able to reconstitute the original tumor in immunodeficient mice [14].

In a review published in 2007, the American Institute for Cancer Research (AICR) drew attention to the benefits of increased cabbage consumption in PDA patients [15]. These results were not restricted to the pancreas, as two recent epidemiological, prospective nutrient studies demonstrated significant inhibition of metastases seeding in patients with prostate cancer [16,17]. Kirsh, et al. observed the significantly decreased risk of extra-prostatic manifestation of prostate cancer (stage III or IV tumors) correlated with an increase in the consumption of cruciferous vegetables, in particular broccoli which is rich in sulforaphane and quercetin (P = 0.02) [16]. The benefits inferred by sulforaphane, which is derived from mustard oil, and its inactive glycoside precursor, glucoraphanin (present in high concentrations in broccoli and its sprouts), have been thoroughly investigated [18,19]. Sulforaphane is believed to target CSCs through the downregulation of NF-kB [18]. This observation was first discovered in PDA and has also been confirmed for breast and prostate cancer [20,21]. Consequently, these substances may serve as an alternative treatment option for PDA; by exhausting pancreatic CSCs, the tumor sensitivity to chemotherapeutics, such as sorafenib, gemcitabine, cisplatin, doxorubicin, and 5-fluorouracil, may be significantly improved [20,22,23].

Trial rationale

Epidemiological and animal studies in various cancer entities [15-17,20,24-29] clearly demonstrate that broccoli sprouts, rich in sulforaphane, have a tumor-suppressive potential [18]. However, to date there has been no routine clinical application of broccoli sprouts or their isolated phytochemical substances. The aim of this pilot study is to evaluate, for the first time, the feasibility and clinical impact of a daily application of encapsulated, freeze-dried broccoli sprouts in PDA patients in a palliative setting as a chemotherapy-supporting agent. The results of the study could consequently serve as the rationale for the design of further clinical trials.

Methods/Design

The ethics committee of the University of Heidelberg has approved the POUNDER trial as a monocentric, prospective, randomized, placebo-controlled clinical pilot study with two parallel groups (placebo versus verum) and provided the trial ethical approval (reference S-347/2009). Forty eligible patients receiving palliative chemotherapy, who meet the inclusion criteria (Table 1), with advanced, non-resectable PDA treated at the European Pancreas Center in Heidelberg, will be enrolled after signing informed consent. Approximately 15 to 20 PDA patients who meet the study inclusion criteria are treated in the outpatient department of the European Pancreas Center per month. Therefore, a short recruitment period of 3 to 4 months is expected. Exclusion criteria are a known intolerance to broccoli or its ingredients, impaired mental status, language problems, or a refusal of participation. Due to the nutrition supplemental character of the trial, sufficient oral intake is a prerequisite for inclusion in the study that is, the patients should not have symptoms or signs of indigestion or problems with the passage of food (nausea, vomiting, presence of nasogastric tube) (Table 1).

### Table 1 Trial inclusion and exclusion criteria

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| Patients ≥18 years | Intolerance to broccoli or its ingredients |
| Advanced, surgically non-treatable PDA* | Impaired mental status or language problems/barriers |
| Written informed consent | |
| Intact gastric emptying | |
| Palliative chemotherapy | |

*Patients who receive surgical exploration, intraoperative biopsy, and/or palliative bypass interventions (bile duct Anastomosis and/or gastroenterostomy because of preoperative cholestasis or impaired gastric emptying due to a tumor-mass effect) will be included in this trial. PDA, pancreatic ductal adenocarcinoma.
Outcome measures
Serum levels of the pancreatic tumor markers carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA), and routinely performed cross-sectional imaging (computed tomography or magnetic resonance imaging), will be monitored and assessed as parameters for evaluating disease status. Staging examinations will take place every three months after study inclusion during the treatment course with cytoreductive chemotherapy (Figure 1).

The total concentration of isothiocyanates (sulforaphane) in urine will serve as a monitoring parameter for the evaluation of patient compliance. Additionally, the overall survival rate will be documented.

To evaluate the quality of life of the study participants, questionnaires (European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ-PAN26, QLQ-C30) will be completed at every follow-up visit (3, 6, and 12 months after patient inclusion).

Figure 1 Flow chart of the POUDER-Trial. PDA, pancreatic ductal adenocarcinoma: AE, adverse event: SAE, serious adverse event: CT, computed tomography; MRI, magnetic resonance imaging. Tumor markers: CEA and CA 19-9.
inclusion), in addition to the evaluation of a patient diary kept to document the regular intake and amount of the test substances, and any observable side effects (adverse or otherwise) (Figure 1). If outcome differences between the verum and the placebo groups are detected after completion of the POUDER trial, statistical analyses will be performed in order to generate a hypothesis for a confirmatory trial on this topic.

**Trial interventions**

Patients will be given 15 capsules of either verum or placebo per day during the chemotherapy treatment course. The follow-up duration is one year. The daily dose of the nutritional supplement for the verum group contains 90 mg of active sulforaphane distributed over 15 capsules, each of which contains 400 mg of broccoli sprout grain (6 mg of sulforaphane per capsule). In contrast, the placebo capsules consist of 400 mg of inactive substances (mainly methylcellulose) with an identical capsule size and intake protocol. Study substances (for the verum and placebo groups) will be produced, labeled, and packed by Food-Service, Deiters & Florin GmbH (Hamburg, Germany). The guidelines for Good Manufacturing Practice (GMP) have been adhered to at all times. Participants will be provided with a 3-month supply of capsules at every visit (Figure 1).

Urine samples will be collected one week and one and six months after randomization to analyze the concentration of the isothiocyanates (Figure 1). The analysis will be done from frozen aliquots using 1,2-benzenedithiol cyclocondensation as described by Shapiro et al. [30] and assessed by high performance liquid chromatography (HPLC). The urine concentration of the degradation products of sulforaphane is used to evaluate the bioavailability of the substance after oral ingestion, as well as patient compliance. In general, sulforaphane levels are significantly higher than those of its inactive precursor, glucoraphanin, thanks in part to the nature of the precursor itself. Both sulforaphane and glucoraphanin are present in known concentrations in the administered broccoli sprouts. However, due to its slower clearance from the body [31], glucoraphanin acts as a depot for the active substance. This, in turn, prolongs the half-life of sulforaphane in the blood. By using HPLC, the conversion of the precursor to the active substance in the body can be measured and monitored.

Biochemical analysis of serum tumor markers will take place during the first visit and for all subsequent visits, scheduled at 3-month intervals, until the end of the follow-up period. Diagnostic imaging (CT/MRI scans) will be routinely performed during the oncological follow-up of the patients. If the findings of the imaging diagnostic are available, they will be included as monitoring parameters and, together with the tumor markers, will provide insight into the status of the disease. The last visit will be scheduled one year after the beginning of the trial and will serve to investigate the clinical status of the patient, as well as to compile all efficacy and safety data.

**Randomization and blinding**

A 1:1 randomization will be performed and patients will be assigned with a randomization number. In case there are dropouts, these patients will be replaced and the new patients will be assigned in an identical manner. If a patient drops out of the study at month 6 due to his/her own decision, the patient data will be removed from the trial completely, including any data generated prior to the withdrawal. If a patient passes away during the first 6 months, the data will be used. If the urine probes reveal that a patient from the broccoli sprouts group did not consume the broccoli sprouts daily or if a patient from the placebo group had a high dietary intake of isothiocyanates, the data from these patients will not be used, but the patient will be replaced by a new patient, even if a patient drops out between months 9 to 12. This case will extend the duration of the study. Randomly generated numbers will be allocated to the two groups in balanced permuted blocks using a number generator (validated software, SAS). In order to avoid any possibility of predicting the group allocation, the length of the blocks will be fixed in a separate document and this information will be withheld from the study site. A data sheet that links the group allocation with the randomized number of the patient will be sealed in pre-produced, non-transparent envelopes labeled with the arbitrary patient numbers and these envelopes will be used in consecutive order. In order to be able to perform a retrospective control of the compliance to randomization, basic patient data, including the day on which the patient’s number was assigned, will be noted on the data sheet. After completing the trial, all unopened envelopes will be delivered to the data management center for comparison to the allocated, randomized patient numbers and examination and evaluation of the thoroughness of the trial.

The investigators, patients, and assessors of the POUDER trial will be blind to the patients’ study treatment courses. The principal investigator (PI) will be provided with a set of sealed envelopes containing information on patients’ trial drugs, one for each patient number. These envelopes are to be opened only under imperative circumstances (medical indication to know the substance in use by the subject).

**Data management and statistical analysis**

The trial investigator or a designated representative (sub-investigator) will document all data acquired during the trial in a case report form (CRF) on the day of the routine
visit. All missing or inconsistent data will be reported and inferred. Upon completion, all CRFs must be officially reviewed and signed by either the investigator named in the trial protocol or by a designated sub-investigator. In order to assure the highest data quality and accurate transfer from the CRF to the database, a double data-entry method will be performed. After completing the trial, the PI will retain the original CRFs.

Totality, validity, and plausibility of the data will be examined by validating programs that will generate queries that must be clarified by the investigator. All findings, both clinical and overall survival, imaging of disease stages, quality of life, and biochemical analyses will be noted in the subject’s CRF.

As this is a pilot study, no sample size calculation was performed. A sample size of 20 patients per study group has been deemed sufficient for the study objectives. The sample size of 20 patients per group is speculative at this time and it is based on comparable patient numbers used in similar ongoing and recently completed patient studies with broccoli sprout extracts. For example, the Pittsburgh pilot study evaluating sulforaphane in atypical nevus precursor lesions enrolled 18 patients (clinicaltrials.gov/ct2/show/NCT01568996?term=NCT01568996&rank=1) and another study performed at OHSU Knight Cancer Institute for examination of sulforaphane in treating patients with recurrent prostate cancer (clinicaltrials.gov/ct2/show/record/NCT01228084?term=sulforaphane&rank=1) enrolled 20 patients.

Depending on data characteristics, descriptive statistics of the monitored parameters will be presented as mean values and SD or median values and IQR. Descriptive P-values of the t-test or the Mann-Whitney U-test comparing the treatment groups will be given, together with the corresponding 95% CI. Categorical parameters will be presented as relative and absolute frequencies, and comparisons will be performed using the Fisher exact test.

Survival curves will be constructed using the Kaplan-Meier estimator. The descriptive P-value of the log-rank test will be used to compare the survival curves of the treatment groups. Estimated median survival times and the one-year survival rates with 95% CI will be given. SAS software (Release 9.1, SAS Institute, Inc. Cary, NC, USA) and Microsoft Office Excel 97® (Redmond, Washington, USA) will be used for the statistical analysis and graphical presentations.

Adverse and serious adverse events
Any manifestation of symptoms or conditions, laboratory parameter alteration, or recurrence or aggravation of existing co-morbidity that correlate with the use of an investigational or medicinal substance or product constitutes an adverse event (AE). A serious adverse event (SAE) is defined as an AE that is life threatening and necessitates hospitalization and/or prolonged medical treatment until stabilization. The occurrence of all events that can be classified as adverse will be recorded and its clinical course will be followed until resolution and stabilization. Events associated with the primary diagnosis, the surgical procedure itself, or complications related to the palliative chemotherapy will not be registered as SAEs unless deemed so by the investigator. All SAEs will be documented and reported to the PI (author PS) within 24 hours or during the following calendar working day, at the latest. The PI will then report the newly documented SAEs to the ethics committee and the investigators. Apart from meteorism, which is a common phenomenon associated with cabbage, a very low risk for AEs is expected during this trial.

Assurance of quality
The principles of the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines [32], the regulations of the Declaration of Helsinki, [33] and local legal and regulatory requirements will be adhered to at all times during the trial period. Medical confidentiality and accordance with the German Federal Data Protection Act will also be observed [34].

Discussion
Since ancient times, cabbages and other extracts of the botanic family Brassicacea have been used as natural antibiotics and key components of antiviral drugs and antymycotics. Members of the Brassicacea family contain glycosides that trigger the release of mustard oils after enzymatical hydrolyzation, in case of physical damage to the plant cells. These mustard oils offer protection against microorganisms and fungi. To date, the bioactive function of more than 120 different mustard oils have been documented [35].

With regard to numerous worldwide studies, an inverse relationship between consumption of cruciferous vegetables (including members of the Brassicacea family) and the risk of neoplastic diseases has been observed, namely in colorectal, gastric, lung, breast, prostate, bladder, and endometrial cancers [18,19]. The bioactive phytochemicals, sulforaphane and quercetin have been shown to be potent substances that possess chemopreventive and therapeutic properties beneficial in cancers of the intestine, breast [28,29], prostate [17], and pancreas [20]. Sulforaphane, and its inactive glycoside precursor, glucoraphanin, are present in high concentrations in broccoli and its sprouts [18,19]. Sulforaphane is a potent antioxidant that indirectly eliminates free radicals; by increasing the concentration of glutathione, sulforaphane inhibits the formation and accumulation of carcinogen-induced DNA adducts [18,36], a finding that has been demonstrated in several animal studies [25,26]. Furthermore, sulforaphane...
is of interest as a new therapeutic anti-cancer substance, based on recent experimental studies in which the compound has been shown to target CSCs in models of pancreatic, breast, and prostate cancer [20,21]. In pancreatic cancer, sulforaphane was shown to exhibit its anti-CSC effect through the downregulation of NF-κB activity, which is usually enhanced in active CSCs [18]. Consequently, sulforaphane might be effective in overcoming the resistance of pancreatic cancer cells to chemotherapy, as underlined by recent experimental studies. These studies show that sulforaphane increases the responsiveness of pancreatic CSCs to sorafenib, gemcitabine, cisplatin, doxorubicin, and 5-fluorouracil [20,22,23].

Another bioactive agent is quercetin, a polyphenol flavonoid commonly found in apples, berries, red grapes, onions, and broccoli, [37] with antioxidant, anticarcinogenic, anti-inflammatory and cardioprotective activities [38,39]. Recent reports describe the possible use of quercetin to inhibit the self-renewal and therapy resistance of pancreatic CSCs by affecting clonogenicity, spheroid formation, and aldehyde dehydrogenase isoform 1 (ALDH1) activity. Consequently, sulforaphane might be effective in overcoming the resistance of pancreatic cancer cells to chemotherapy, as underlined by recent experimental studies. These studies show that sulforaphane increases the responsiveness of pancreatic CSCs to sorafenib, gemcitabine, cisplatin, doxorubicin, and 5-fluorouracil [20,22,23].

In closing, the POUDER trial is the first clinical pilot trial to test the feasibility of an intake of freeze-dried broccoli sprouts as an additive of palliative chemotherapy in surgically non-resectable, advanced pancreatic cancer. Depending on the results of this pilot trial, a hypothesis for a confirmatory trial in the field will be generated and a consecutive RCT is planned.

**Trial status**

The POUDER trial has been designed as a single center pilot randomized controlled trial (RCT). The initiation took place at the Department of Surgery, University of Heidelberg in December 2013 after approval by the local ethical committee.

**Abbreviations**

AE: adverse event; ALDH1: aldehyde dehydrogenase isoform 1; CA 19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; CRF: case report form; CSC: cancer stem cells; CT: computed tomography; HPLC: high performance liquid chromatography; MRI: magnetic resonance imaging; NF-κB: Nuclear factor-kappa beta; PDA: pancreatic ductal adenocarcinoma; PI: principal investigator; RCT: randomized controlled trial; SAE: serious adverse event.
Competing interests
The authors have no competing interests to declare.

Authors’ contributions
VJL, PH, IH, and PS designed the study. PS performed a quality review to ensure adherence to current guidelines and laws. UH supported the statistical design. IH supported the design of the study. VJL, IH, and PS wrote the manuscript. All authors have read and approved its final version.

Acknowledgement
Funding: the scheduled pilot study will be supported by a grant from the Heidelberger Stiftung Chirurgie and by a donation of capsules with both, broccoli sprouts and placebo from N Deiters for the verum and placebo groups, respectively. The authors would like to thank Nadya Phillips-Houben for language editing.

Received: 9 February 2014 Accepted: 12 May 2014
Published: 3 June 2014

References
1. Haritharan D, Saeid A, Kocher HM: Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 2008; 10:58–62.
2. Witkowski ER, Smith JK, Tseng JF: Myeloid leukaemia after transplantation into SCID mice. Highlights from the 2011 ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA. January 20-22, 2011. JOP 2011; 12:96–110.
3. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Klein J, Mansmann U, Jäger D, Carabusso L, Kurz R, Büchler MW: Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012, 30:4077–4083.
4. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11–30.
5. Tuveson DA, Neoptolemos JP: Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 2012; 148:21–23.
6. Li D, Xie J, Wolf R, Abuzinada J: Pancreatic cancer. Cancer 2004, 103:1049–1057.
7. Obertser PE, Salf MW: First-line treatment for advanced pancreatic cancer. Highlights from the “2011 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 20-22, 2011. JOP 2011, 12:96–110.
8. Laplido T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: Initiating a cell to initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645–648.
9. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105–111.
10. Rosheed ZA, Kowalski J, Smith BD, Matsui W: Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011, 29:883–887.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983–3988.
12. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432:396–401.
13. Simeone DM: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 2008, 14:5546–5548.
14. Abbott A: Cancer: the root of the problem. Nature 2006, 442:742–743.
15. Forman D, Burley V, Cade I, Greenwood D, Moreton J, Chan D, Tu YK, Gordon I, Thomas J, McColl K, through 2003, 5646:135–137.
16. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432:396–401.
17. Simeone DM: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 2008, 14:5546–5548.
18. Abbott A: Cancer: the root of the problem. Nature 2006, 442:742–743.
19. Forman D, Burley V, Cade I, Greenwood D, Moreton J, Chan D, Tu YK, Gordon I, Thomas J, McColl K: The associations between food, nutrition and physical activity and the risk of pancreatic cancer and underlying mechanisms. In World Cancer Research Fund. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR, 2007.
20. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432:396–401.
21. Simeone DM: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 2008, 14:5546–5548.
22. Abbott A: Cancer: the root of the problem. Nature 2006, 442:742–743.
23. Forman D, Burley V, Cade I, Greenwood D, Moreton J, Chan D, Tu YK, Gordon I, Thomas J, McColl K: The associations between food, nutrition and physical activity and the risk of pancreatic cancer and underlying mechanisms. In World Cancer Research Fund. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR, 2007.
24. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432:396–401.
25. Simeone DM: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 2008, 14:5546–5548.
26. Abbott A: Cancer: the root of the problem. Nature 2006, 442:742–743.
27. Forman D, Burley V, Cade I, Greenwood D, Moreton J, Chan D, Tu YK, Gordon I, Thomas J, McColl K: The associations between food, nutrition and physical activity and the risk of pancreatic cancer and underlying mechanisms. In World Cancer Research Fund. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR, 2007.
28. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432:396–401.
29. Simeone DM: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 2008, 14:5546–5548.
36. Shishu, Singla AK, Kaur IP: Inhibition of mutagenicity of food-derived heterocyclic amines by sulphoraphenean isothiocyanate isolated from radish. *Planta Med* 2003, 69:184–186.

37. Watzl B, Leitzmann C: Bioaktive Substanzen in Lebensmitteln. 3rd edition. Stuttgart: Hippokrates Verlag; 2005.

38. Williamson G, Manach C: Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. *Am J Clin Nutr* 2005, 81:243–255.

39. Ramos S: Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. *J Nutr Biochem* 2007, 18:427–442.

40. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Avi L: Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. *Gastroenterology* 2012, 143:234–245.

41. Halkier BA, Gershenzon J: Biology and biochemistry of glucosinolates. *Annu Rev Plant Biol* 2006, 57:303–333.

42. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? *J Natl Cancer Inst* 2008, 100:773–783.

43. D’Andrea GM: Use of antioxidants during chemotherapy and radiotherapy should be avoided. *CA Cancer J Clin* 2005, 55:319–321.

doi:10.1186/1745-6215-15-204
Cite this article as: Lozanovski et al.: Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) - study protocol for a randomized controlled trial. *Trials* 2014, 15:204.